SETD2 and renal cell carcinoma: Correlation between RUNX3 pathway signature and somatic mutations in RCC was shown in Fig. 5A. In the JAVELIN-101 cohort of advanced RCC, frequent mutations included VHL (55%), MUC16(44%), PBRM1 (32%), SETD2 (25%) and BAP1 (16%).